The latest biotechnological developments of the Medsintez are presented at the international forum Russian Healthcare Week - 2023

Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.

At the collective exposition PharmMedProm held under the auspices of the Ministry of Industry and Trade of Russia, among the leading Russian medical and pharmaceutical manufacturers, the Medsintez Plant presented its main products — genetically engineered and analogue human insulin for treating diabetes Rosinsulin, the first Russian recombinant follicle-stimulating hormone for infertility treatment Primapur, an innovative direct-acting antiviral drug Triazavirin for treating influenza, ARVI and COVID-19, and also presented its latest developments that only the Medsintez Plant currently produces in Russia.

In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs for treating type II diabetes mellitus: Liraglutide and Semaglutide. Due to the departure of foreign manufacturers from Russia, these drugs were included in the list of out of stock drugs, while the incidence of type II diabetes today is 90 % of the total number of diabetic patients. The production capacity of the Medsintez Plant can meet 100% of Russia’s demand for these drugs.

Today, the Medsintez Plant is developing a pool of drugs used in a complex of assisted reproductive technologies. The creation of a full line of drugs for infertility treatment will ensure drug safety in this area in Russia and allow not to depend on import supplies. At the booth of the Ministry of Industry and Trade, the Medsintez Plant presented recombinant human chorionic gonadotropin (HCG) used in the ART complex (including for IVF), which is currently being prepared for preclinical studies.

In 2023, the company launched the production of the first Russian species-specific insulins for veterinary use, Vinsuvet (separately for cats and dogs). In the absence of the foreign preparations on the Russian market, our own production of veterinary insulin will become a reliable support for pet owners in caring for their pets’ health.

The Medsintez Plant is ready to launch its own production of reagents for the creation of pharmaceuticals, which will ensure the replacement of inaccessible imported components on the Russian market. Now the Plant is working on the production of pharmacopoeial acetonitrile, which is necessary for the operation of a large number of research laboratories. In addition, if necessary, the Plant can produce any import-substituting preparations based on monoclonal antibodies.

The Medsintez Plant has for 20 years specialized in developing and manufacturing most complex pharmaceutical products that meet international GMP requirements and ISO standards. High-tech production ensures a high level of quality and safety of manufactured products. The Plant’s technological capacities, competencies in biotechnological processes, interaction with scientific institutions, as well as the ability to develop and produce own devices for administering injectable drugs opens up the horizons for the Medsintez Plant in developing new innovative medicines. Fruitful cooperation with state authorities on programs of affordable drug supply to the population is underway.